Direct Oral Anticoagulants for Cerebral Venous Thrombosis: Equivalent Efficacy, Superior Safety Compared to Vitamin K Antagonists (P3-4.003) | Synapse
June 13, 2026
Direct Oral Anticoagulants for Cerebral Venous Thrombosis: Equivalent Efficacy, Superior Safety Compared to Vitamin K Antagonists (P3-4.003)
Key Points
This research aims to systematically review and compare the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) for treating cerebral venous thrombosis (CVT).
Conducted the largest systematic review and meta-analysis to date on the topic.
Compared the efficacy, safety, and treatment durability of DOACs and VKAs in patients with CVT.
DOACs demonstrate equivalent efficacy compared to VKAs in treating CVT.
DOACs show superior safety profiles, leading to fewer complications than VKAs.
Abstract
To perform the largest systematic review and meta-analysis comparing DOACs and VKAs in CVT, evaluating efficacy, safety, and treatment durability to date.